Assenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Assenagon Asset Management S.A. reduced its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 63.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,850 shares of the biotechnology company’s stock after selling 1,044,318 shares during the period. Assenagon Asset Management S.A. owned approximately 0.77% of CytomX Therapeutics worth $618,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of CTMX. FMR LLC boosted its stake in CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after buying an additional 41,949 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares during the period. US Bancorp DE acquired a new stake in shares of CytomX Therapeutics in the 3rd quarter valued at $40,000. Cubist Systematic Strategies LLC grew its holdings in shares of CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the last quarter. Finally, XTX Topco Ltd increased its position in shares of CytomX Therapeutics by 382.6% during the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics Price Performance

CTMX opened at $0.89 on Friday. The company’s 50 day simple moving average is $1.02 and its 200-day simple moving average is $1.14. CytomX Therapeutics, Inc. has a one year low of $0.79 and a one year high of $5.85. The stock has a market capitalization of $69.74 million, a P/E ratio of 5.24 and a beta of 1.03.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.23. The business had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same quarter last year, the business earned $0.04 earnings per share. As a group, analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.77.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.